Tumor-targeted REXIN-G Quells Metastatic Osteosarcoma, Prostate Cancer, and Pancreas Cancer as Stand-alone Therapy
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so...
Whistleblower Mark Whitacre says 'The Informant' Movie is Only Part of the Story
NEW YORK CITY, N.Y. -- As Mark Whitacre, COO of Cypress Systems, Inc., walked the red carpet on September 15 during the premiere of...
Pharmaceutical eMarketing using Social Media: How to Use It Effectively
NEW YORK, N.Y. -- Eularis is announcing the release of its report "How To Harness The Power Of Social Media In Pharmaceutical eMarketing." This...
Patented Green Technology is Potential Silver Bullet for Swine Flu and Most Common Infections
FORT LAUDERDALE, Fla. -- Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver,...
Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product,...
Epeius Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food...
The World's Smallest Hero! Epeius Bio's Rexin-G, Targeted Therapy for Metastatic Cancers
SAN MARINO, Calif. -- Epeius Biotechnologies' Rexin-G® is the world's smallest hero (epeiusbiotech.com). Imagine if you will, a tiny particle that can travel freely...
Eularis Releases Comprehensive Report on Effective Pharmaceutical eMarketing
NEW YORK, N.Y. -- Eularis is announcing the release of an update to its report "Pharmaceutical eMarketing: Building Brands, Relationships & Business Through Web...
Eularis to Hold Pharma Marketing ROI MasterClass in London
LONDON, U.K. -- Dr. Andree Bates, President of the Pharmaceutical analytics company Eularis, will be delivering a MasterClass on how to tell if you...
Epeius' Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out...
Hot Rising Fitness Star Natalie Waples Takes On Steroids Issue in Fitness Biz
ORLANDO, Fla. -- Natalie Waples is one of the brightest young stars in the fitness firmament. The eye-catching Canadian made her pro debut last...
Cancer-Destroying Biotech: Epeius Bio Launches Rexin-G eBook Tutorial
SAN MARINO, Calif. -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to...
Epeius Bio's Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemo-Resistant Pancreatic Cancer
SAN MARINO, Calif. -- Epeius Biotechnologies (epeiusbiotech.com) announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in...
Silver Safety Committee Gives Guidelines for Safe Use of Any Ionic or Colloidal Silver Supplement
FORT LAUDERDALE, Fla. -- The Silver Safety Committee this week announced its creation of the Silver Safety Pyramid, which is designed to enable anyone...
Epeius Bio Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting...
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Cancers
SAN MARINO, Calif. -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma...
Eularis Analyzes Pre-Launch Brand Planning with New Pharma Industry Report
LONDON, U.K. -- In today's environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and...
Rexin-G Clinical Trials for Pancreatic Cancer and Breast Cancer Open in New York
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in...
SELECT TRIAL used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R)
FRESNO, Calif. -- Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results - that were announced yesterday -...
Epeius Biotechnologies Reveals a New Generation of Tools for Medical Gene Delivery
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The...
Eularis Releases First-Ever Pharma Study: ROI of Pre-Launch Named Patient Programs
NEW YORK, N.Y. and LONDON, U.K. -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP),...
Epeius Biotechnologies Rexin-G® for Metastatic Cancer Highlighted by National Cancer Institute Journal
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a...
Eularis Analyzes Most Effective Generics Defense Strategies with New Pharma Industry Report
NEW YORK, N.Y. and TOKYO, JAPAN -- Branded Pharmaceutical companies are painfully aware of the astronomical growth of Generics competition. By the end of...
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
SAN MARINO, Calif. -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration...
Eularis Challenges Pharma Industry in 2008: Are You Measuring the Wrong Things
LONDON UK, and TOKYO Japan -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority...
